EXECUTION VERSION DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT BETWEEN AETERNA ZENTARIS GMBHDevelopment, Commercialization and License Agreement • March 17th, 2009 • Aeterna Zentaris Inc. • Pharmaceutical preparations • New York
EX-10.4 7 a2231300zex-10_4.htm EX-10.4 ***TEXT OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. SECTIONS 200.80(B)(4) AND RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED...Development, Commercialization and License Agreement • May 5th, 2020 • New York
THIS DEVELOPMENT, COMERCIALIZATION AND LICENSE AGREEMENT (the “Agreement”) is made and entered into effective as of December 18, 2015 (the “Effective Date”), by and between AKCEA THERAPEUTICS, INC., a Delaware corporation (“Akcea”), and ISIS PHARMACEUTICALS, INC., a Delaware corporation (“Isis”). Akcea and Isis each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
EX-10.67 2 dex1067.htm DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT WITH LUPIN LTD. *Portions of this document marked [*] are requested to be treated confidentially. FINAL EXECUTION COPY DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT...Development, Commercialization and License Agreement • May 5th, 2020 • New York
This Development, Commercialization and License Agreement (this “Agreement”) is made and entered into effective as of September 30, 2009 (the “Effective Date”) by and between Lupin Ltd., a corporation organized under the laws of India and having its principal place of business at “B” Wing, Fifth Floor, Bandra Kurla Complex, Mumbai—400 051, India (“Lupin”), and Salix Pharmaceuticals, Inc., a corporation organized under the laws of the State of California in the United States of America and having its principal place of business at 1700 Perimeter Park Drive, Morrisville, North Carolina 27560-8404, U.S.A. (“Salix”). Lupin and Salix are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
January 16, 2017Development, Commercialization and License Agreement • March 27th, 2017 • Akcea Therapeutics, Inc. • Pharmaceutical preparations
Reference is made to the Development, Commercialization and License Agreement dated December 18, 2015 (the “Akcea-Ionis Agreement”), by and between Ionis Pharmaceuticals, Inc. (“Ionis”), and Akcea Therapeutics, Inc. (“Akcea”). On January 5, 2017, Akcea entered into that certain Strategic Collaboration, Option and License Agreement (the “Novartis Agreement”) by and between Akcea and Novartis Pharma AG (“Novartis”), pursuant to which Akcea and Novartis formed a strategic collaboration in cardio-metabolic lipid diseases. This letter agreement serves to confirm certain additional agreements between Ionis and Akcea and, to the extent the terms of the Akcea-Ionis Agreement conflict with the terms of the Novartis Agreement, this letter agreement addresses how such conflicts are resolved. Capitalized terms used but not otherwise defined herein will have the meanings ascribed to such terms in the Novartis Agreement.
DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENTDevelopment, Commercialization and License Agreement • October 31st, 2000 • Corixa Corp • Biological products, (no disgnostic substances) • Arizona
Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. FIRST AMENDMENT TO AMENDED AND RESTATED DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT between LUPIN LTD. and SALIX PHARMACEUTICALS, INC. Dated as of...Development, Commercialization and License Agreement • May 10th, 2013 • Salix Pharmaceuticals LTD • Pharmaceutical preparations
This FIRST AMENDMENT TO AMENDED AND RESTATED DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT (this “Amendment”), dated as of 22 February 2013 (the “First Amendment Effective Date”), is made by and between Lupin Ltd., a corporation organized under the laws of India (“Lupin”), and Salix Pharmaceuticals, Inc., a California corporation (“Salix”). Lupin and Salix are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT BETWEEN [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.***] AND CIMA LABS INC.Development, Commercialization and License Agreement • August 14th, 2003 • Cima Labs Inc • Pharmaceutical preparations • Delaware
Exhibit 10.1 * CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. DEVELOPMENT,...Development, Commercialization and License Agreement • December 17th, 2001 • Corixa Corp • Biological products, (no disgnostic substances) • Delaware
FIRST AMENDMENT TO DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT BY AND AMONG Cti biopharma corp., BAXALTA INCORPORATED BAXALTA US INC. AND BAXALTA GMBHDevelopment, Commercialization and License Agreement • August 6th, 2015 • Cti Biopharma Corp • Pharmaceutical preparations • New York
This FIRST AMENDMENT TO DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT (this “Amendment”) is entered into on this 8th day of June, 2015 (the “Effective Date”), by and among CTI BIOPHARMA CORP (f/k/a CELL THERAPEUTICS, INC.), a company organized under the laws of the State of Washington with its principal place of business at 3101 Western Avenue, Seattle, WA 98121 (“CTI”), and BAXALTA INCORPORATED, a company organized under the laws of Delaware with its principal place of business at 1200 Lakeside Drive, Bannockburn, IL 60015 (“BI”), BAXALTA US INC. (“BUSI”) and BAXALTA GMBH (“BGMBH” and, together with BI and BUSI, collectively, “Baxalta”). CTI and Baxalta may each be referred to herein individually as a “Party” and collectively as the “Parties.”
DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT BY AND AMONG CELL THERAPEUTICS, INC., BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE CORPORATION AND BAXTER HEALTHCARE SA DATED: NOVEMBER 14, 2013Development, Commercialization and License Agreement • March 4th, 2014 • Cell Therapeutics Inc • Pharmaceutical preparations • New York
This DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT (this “Agreement”) is entered into on this 14th day of November, 2013 (the “Effective Date”), by and among CELL THERAPEUTICS, INC., a company organized under the laws of the State of Washington with its principal place of business at 3101 Western Avenue, Seattle, WA 98121 (“CTI”), and BAXTER INTERNATIONAL INC., a company organized under the laws of Delaware with its principal place of business at One Baxter Parkway, Deerfield, IL 60015 (“BII”), BAXTER HEALTHCARE CORPORATION, a company organized under the laws of Delaware with its principal place of business at One Baxter Parkway, Deerfield, IL 60015 (“BHC”), and BAXTER HEALTHCARE SA, a company organized under the laws of Switzerland with its principal place of business at Postfach 8010, Zurich, Switzerland (“BHSA” and together with BII and BHC, “Baxter”). CTI and Baxter may each be referred to herein individually as a “Party” and collectively as the “Parties.”
October 19, 2016 Mr. Matthew Plunkett CT1 BioPharma, Inc. 3103 Western Avenue Suite #600 Seattle, WA 98121 Re: Side Letter #2 on Term Sheet Timing Issues Dear Mr. Plunkett:Development, Commercialization and License Agreement • October 24th, 2016 • Cti Biopharma Corp • Pharmaceutical preparations
Pursuant to Section 16.7 of the Development, Commercialization and License Agreement, dated November 14, 2013, as previously amended by that certain letter agreement re Side Letter on Term Sheet Timing Issues, dated September 19, 2016, between CTI BioPharma Corp. and Baxalta US Inc., as well as all other previous amendments (the “DCLA”), this letter, for good and valuable consideration, further amends that agreement.
DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENTDevelopment, Commercialization and License Agreement • November 2nd, 2000 • Medicis Pharmaceutical Corp • Pharmaceutical preparations • Arizona
AMENDED AND RESTATED DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT by and between ACHILLION PHARMACEUTICALS, INC. and GCA THERAPEUTICS, LTD. Dated March 5, 2010Development, Commercialization and License Agreement • March 11th, 2010 • Achillion Pharmaceuticals Inc • Pharmaceutical preparations • New Jersey
THIS AMENDED AND RESTATED DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT (“Agreement”) is executed March 5, 2010 and is made effective as of February 1, 2010 (“Effective Date”) by and between ACHILLION PHARMACEUTICALS, INC., a Delaware corporation (“Achillion”), with its principal place of business at 300 George Street, New Haven, Connecticut 06511, USA, and GCA THERAPEUTICS, LTD., a New Jersey corporation (“GCAT”), with its principal place of business at 14 Wall Street, 20th Floor, New York, NY 10005, USA. Achillion and GCAT are sometimes referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
RELAXINDevelopment, Commercialization and License Agreement • May 15th, 2000 • Connetics Corp • Pharmaceutical preparations
